Tone mix
Week by week 52 weeks
Share of BioNTech SE American Depositary Share's 343 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Apr 13, 2026 · tone +99BioNTech's (BNTX) Buy Rating Reiterated at Berenberg Bank+110
- Week of Apr 27, 2026 · tone +100BioNTech (BNTX) Price Target Raised Following Successful T-Pam Data+105
- Week of Jun 22, 2026 · tone -98Alarm at BMW! Sell-off at BioNTech! Desert Gold Undervalued! | 2026-06-24 | Investing News-82
- Week of Apr 6, 2026 · tone -99HC Wainwright Cuts BioNTech (NASDAQ:BNTX) Price Target to $130.00-81
- Week of Mar 23, 2026 · tone +73BioNTech's (BNTX) Buy Rating Reaffirmed at Jefferies Financial Group+78
- Week of Jun 1, 2026 · tone +83Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial+76
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about BioNTech SE American Depositary Share in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 18 | +68 |
| Last 30 sessions | 66 | +15 |
| Last 90 sessions | 139 | +17 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- 247wallst.com · 1 outletModerna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge HigherPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher | 247wallst.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
2 headlines, average tone -50: 0 positive, 1 neutral and 1 negative. Showing all 2.
- 247wallst.com · 1 outletModerna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds SteadyNegative
- www.biopharmadive.com · 1 outletBioNTech, DualityBio say ADC had 'modest' benefit in breast cancer studyNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady | 247wallst.com | 1 | Negative |
| BioNTech, DualityBio say ADC had 'modest' benefit in breast cancer study | www.biopharmadive.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
9 headlines, average tone +84: 8 positive, 1 neutral and 0 negative. The 8 most widely carried stories are listed; the table holds all 9.
- portal.sina.com.hk · 2 outletsBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapyPositive
- www.finanznachrichten.de · 1 outletBioNTech SE: BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapyPositive
- www.investegate.co.uk · 1 outletBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy | Company AnnouncementPositive
- indiaeducationdiary.in · 1 outletBioNTech mRNA manufacturing facility opens - India Education | Latest Education News | Global Educational NewsPositive
- www.manilatimes.net · 1 outletBioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast CancerPositive
- econotimes.com · 1 outletBioNTech, DualityBio Say Breast Cancer Trial Met Goal Amid Lung Disease CasesPositive
- www.investegate.co.uk · 1 outletBioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer | Company AnnouncementPositive
- finchannel.com · 1 outletBristol Myers and BioNTech report early lung-cancer trial resultsPositive
Show the table · 9 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy | portal.sina.com.hk | 2 | Positive |
| BioNTech SE: BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy | www.finanznachrichten.de | 1 | Positive |
| BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy | Company Announcement | www.investegate.co.uk | 1 | Positive |
| BioNTech mRNA manufacturing facility opens - India Education | Latest Education News | Global Educational News | indiaeducationdiary.in | 1 | Positive |
| BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer | www.manilatimes.net | 1 | Positive |
| BioNTech, DualityBio Say Breast Cancer Trial Met Goal Amid Lung Disease Cases | econotimes.com | 1 | Positive |
| BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer | Company Announcement | www.investegate.co.uk | 1 | Positive |
| Bristol Myers and BioNTech report early lung-cancer trial results | finchannel.com | 1 | Positive |
| BioNTech Plans Pumitamig-Trodelvy Regimen in Breast Cancer Trial | econotimes.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +77: 1 positive, 0 neutral and 0 negative. Showing all 1.
- econotimes.com · 1 outletBioNTech Plans Trodelvy Combination in Global Phase 3 Breast Cancer TrialPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| BioNTech Plans Trodelvy Combination in Global Phase 3 Breast Cancer Trial | econotimes.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
3 headlines, average tone +99: 3 positive, 0 neutral and 0 negative. Showing all 3.
- www.rttnews.com · 1 outletBioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With GileadPositive
- www.investegate.co.uk · 1 outletBioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Company AnnouncementPositive
- www.finanznachrichten.de · 1 outletBioNTech SE: BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast CancerPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| BioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead | www.rttnews.com | 1 | Positive |
| BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Company Announcement | www.investegate.co.uk | 1 | Positive |
| BioNTech SE: BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about BioNTech SE American Depositary Share, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.